NCT07158229View on ClinicalTrials.gov

Long-term Impact of NMDAR Encephalitis, Level 3

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions

NMDAR Autoimmune Encephalitis

Interventions

OTHER

Questionnaires

Complete quality of life questionnaires focusing on fatigue, anxiety, depression, and sleep.

Trial Locations (1)

69500

Centre de référence des syndromes neurologies paranéoplasiques et encéphalites auto-immunes - Hôpital neurologiques Pierre WERTHEIMER - Groupement hospitalier Est - Hospices civiles de Lyon, Bron

All Listed Sponsors

collaborator

Charite University, Berlin, Germany

OTHER

lead

Hospices Civils de Lyon

OTHER

NCT07158229 - Long-term Impact of NMDAR Encephalitis, Level 3 | Biotech Hunter | Biotech Hunter